<DOC>
	<DOCNO>NCT02181231</DOCNO>
	<brief_summary>The investigator conduct research study learn safety benefit use medication call buprenorphine patient difficult treat depression . This research study test whether combine two medication effective treat depression initial treatment one antidepressant relieve depressive symptom ; call `` difficult treat depression '' `` treatment resistant depression '' . The two medication investigator use : anti-depressant medication call venlafaxine extend release ( venlafaxine XR ) , generic form Effexor , buprenorphine . Buprenorphine medication FDA approve treatment opioid dependence . The investigator test whether add buprenorphine venlafaxine XR enhance treatment response .</brief_summary>
	<brief_title>Buprenorphine Used With Treatment Resistant Depression Older Adults</brief_title>
	<detailed_description>We consent approximately 100 participant , age 50 old , sexes race . Participation may last 32 week . We utilize clinical trial 3 Phases . In Phase 1 treat participant approximate 12 week course open-label venlafaxine XR . This lead-in treatment ongoing `` IRL Grey '' ( `` Incomplete Response Late Life Depression : Getting Remission '' ) multi-site R01 late-life treatment resistant depression ( LL-TRD ) , find highly successful . Participants find relief depressive symptom venlafaxine XR alone exit study . Participants meet criterion incomplete response ( still feel depressed withdrawn ) , randomly assign receive either low-dose buprenorphine placebo augmentation venlafaxine xr 8 week ( Phase 2 ) , goal achieve remission . There 3 combine positron emission tomography magnetic resonance imaging scan ( PET/MRI ) Phase 2 well one computerize tomography ( CT ) scan order determine effect buprenorphine brain . At conclusion Phase 2 , blind broken participant . The participant placebo able begin take buprenorphine immediately Phase 3 ( approximately 8 week ) . The participant already buprenorphine Phase 2 continue take Phase 3 . Buprenorphine ( BPN ) taper upon exit study , guidance P.I . The Phase 3 variation allow participant chance experience benefit buprenorphine ( BPN ) . Efficacy tolerability data provide clinically informative estimate benefit risk buprenorphine augmentation late-life treatment resistant depression ( LL-TRD ) . We randomize approximately 20 subject Phase 2 . Additionally , collect buprenorphine ( BPN ) plasma level randomize explore dose-effect relationship treatment response . A small pilot study ( age 21 ) 5 healthy control subject study 2 week period order ensure procedure work determine clinical effect buprenorphine . Control subject undergo baseline PET/MRI take buprenorphine . At least 24 hour image , control subject receive small dose BPN start 0.2 mg/day titrate tolerate 1.2 mg/day first week . Each subject remain approximately 1.2 mg/day duration week 2 . At end 2 week period , subject undergo second PET/MRI .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Age &gt; = 50 year . 2 . Major depressive disorder ( MDD ) , single recurrent , diagnose Structured Clinical Interview Diagnostic Statistical Manual Mental Disorders ( SCIDIV ) . 3 . Montgomery Asberg Depression Rating Scale ( MADRS ) &gt; /= 15 . 4 . Has agree establish clinical relationship primary care physician ( PCP ) . 5 . Availability informant ( e.g. , emergency contact ) . 1 . Inability provide inform consent . 2 . Depressive symptom severe enough ( i.e. , MADRS &lt; 15 ) baseline assessment 3 . Dementia , define Mini Mental State Exam ( 3MS ) &lt; 84 clinical evidence dementia ( e.g. , memory impairment , executive dysfunction , agnosia , apraxia , aphasia , functional impairment ) . 4 . Lifetime diagnosis bipolar I II disorder , schizophrenia , schizoaffective disorder , schizophreniform disorder , delusional disorder , current psychotic symptom , diagnose SCID . 5 . Abuse dependence alcohol substance within past 3 month determine SCID , confirm study physician interview . 6 . Drinking 15 drink per week consume 5 drink one occasion past week . 7 . High risk suicide ( e.g. , active SI and/or current/recent intent plan ) unable manage safely clinical trial ( e.g. , unwilling hospitalize ) . Urgent psychiatric referral make case . 8 . Contraindication venlafaxine XR BPN determine PCP study physician include history intolerance either venlafaxine XR BPN study target dosage range ( venlafaxine XR 300 mg/day ; BPN 2 mg/day ) . 9 . Inability communicate English ( i.e. , interview conduct without interpreter ; subject largely unable understand question respond English ) . 10 . Noncorrectable clinically significant sensory impairment ( i.e. , hear well enough cooperate interview ) . 11 . Unstable medical illness , include delirium , uncontrolled diabetes mellitus , hypertension , hyperlipidemia , cerebrovascular cardiovascular risk factor medical management . This determine base information patient 's personal physician study physician 's clinical judgment . Referral patient 's personal physician general practitioner make case . 12 . Subjects take psychotropic medication safely taper discontinue prior study initiation . The following exception allow take stable dose least 4 week prior study entry plan change dose next 28 week : benzodiazepine 2 mg/d lorazepam equivalent ; sedativehypnotics ( e.g. , zolpidem , zaleplon , eszopiclone ) ; gabapentin prescribed nonpsychiatric indication ( e.g. , neuropathy ) . 13 . History opioid abuse dependence . 14 . Severe pain , define &gt; 7 010 numeric rating scale pain . 15 . Concomitant use strong moderate CYP3A4 inhibitor ( indinavir , nelfinavir , ritonavir , clarithromycin , itraconazole , ketoconazole , nefazodone , saquinavir , telithromycin , aprepitant , erythromycin , fluconazole , grapefruit juice , verapamil , diltiazem ) . 16 . Refusal stop opioids ( avoid precipitate opioid withdrawal ) . 17 . Hepatic impairment 18 . Estimated Glomerular Filtration Rate ( GFR ) &lt; 20 ml/min . 19 . Inability/refusal identify person emergency contact . 20 . Pregnancy 21 . Contraindication MRI/PET CT scan</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>old adult</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>Effexor XR</keyword>
	<keyword>treatment resistant</keyword>
	<keyword>venlafaxine</keyword>
	<keyword>Saint Louis</keyword>
	<keyword>late life</keyword>
	<keyword>major depression</keyword>
</DOC>